Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | KLK1 | P06870 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781249 | 0.83 | KCNH2 (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL31220043 | 0.83 | THRB (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4505785 | 0.80 | ACHE (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7456644 | 0.78 | L3MBTL1 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7460116 | 0.76 | HCAR2 (0.44) | KDM4EALDH1A1LMNAALOX15CA1 | |
| SCHEMBL7460725 | 0.76 | LMNA (0.41) | KDM4EALDH1A1LMNACA1CA2 | |
| SCHEMBL30948998 | 0.75 | P4HTM (0.41) | ALDH1A1LMNACA1CA2 | |
| SCHEMBL23062609 | 0.75 | THRB (0.32) | THRBRORCF2PLGPLAU | |
| SCHEMBL7465226 | 0.75 | ALDH1A1 (0.37) | KDM4EALDH1A1CA1CA2CA9 | |
| SCHEMBL7461252 | 0.75 | L3MBTL1 (0.47) | ALDH1A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060360-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-08-13 | — | — | US | disclosed |
| CN-111212836-B | Lysyl oxidase inhibitors | 癌症研究所：皇家癌症医院 | 2023-12-15 | — | — | CN | disclosed |
| US-20220289757-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-09-15 | — | — | US | disclosed |
| US-11325915-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-05-10 | — | — | US | disclosed |
| US-11325915-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-05-10 | — | — | US | disclosed |
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| CN-111212836-A | Lysyl oxidase inhibitors | 癌症研究所：皇家癌症医院 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019073251-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
| US-8716482-B2 | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2480082-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| WO-2011037793-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885USP2 1027/4885ALDH1A1 1199/4885 |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | KDM4E 525/4885USP2 1496/4885ALDH1A1 681/4885 |
| US-12060360-B2 | Lysyl oxidase inhibitors | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885USP2 1027/4885ALDH1A1 1199/4885 |
| US-20220289757-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885USP2 1027/4885ALDH1A1 1199/4885 |
| US-11325915-B2 | Lysyl oxidase inhibitors | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885USP2 1027/4885ALDH1A1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.